Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Mpox Vaccine Maker Ready To Produce 10 Million Doses

Handout undated photo of Bavarian Nordic research in Kvistgard, Denmark. Danish drugmaker Bavarian Nordic said Thursday it was ready to produce up to 10 million doses of its vaccine targeting mpox by 2025 after the World Health Organization declared a surge in the virus in Africa a global public health emergency. Alarmed by a rise in cases in the Democratic Republic of Congo and the spread of mpox to nearby countries, WHO experts said Wednesday that the "situation constitutes a public health emergency of international concern". Photo by Bavarian Nordic via ABACAPRESS.COM

E

Mpox Vaccine Maker Ready To Produce 10 Million Doses

Handout file photo dated December 12, 2019 of Bavarian Nordic vaccine manufacturing line in Kvistgard, Denmark. Danish drugmaker Bavarian Nordic said Thursday it was ready to produce up to 10 million doses of its vaccine targeting mpox by 2025 after the World Health Organization declared a surge in the virus in Africa a global public health emergency. Alarmed by a rise in cases in the Democratic Republic of Congo and the spread of mpox to nearby countries, WHO experts said Wednesday that the "situation constitutes a public health emergency of international concern". Photo by Bavarian Nordic via ABACAPRESS.COM

E

Mpox Vaccine Maker Ready To Produce 10 Million Doses

Handout file photo dated December 12, 2019 of Bavarian Nordic vaccine manufacturing line in Kvistgard, Denmark. Danish drugmaker Bavarian Nordic said Thursday it was ready to produce up to 10 million doses of its vaccine targeting mpox by 2025 after the World Health Organization declared a surge in the virus in Africa a global public health emergency. Alarmed by a rise in cases in the Democratic Republic of Congo and the spread of mpox to nearby countries, WHO experts said Wednesday that the "situation constitutes a public health emergency of international concern". Photo by Bavarian Nordic via ABACAPRESS.COM

E

Mpox Vaccine Maker Ready To Produce 10 Million Doses

Handout file photo dated July 7, 2021 of Bavarian Nordic manufacturing site in Kvistgard, Denmark. Danish drugmaker Bavarian Nordic said Thursday it was ready to produce up to 10 million doses of its vaccine targeting mpox by 2025 after the World Health Organization declared a surge in the virus in Africa a global public health emergency. Alarmed by a rise in cases in the Democratic Republic of Congo and the spread of mpox to nearby countries, WHO experts said Wednesday that the "situation constitutes a public health emergency of international concern". Photo by Bavarian Nordic via ABACAPRESS.COM

E

Mpox Vaccine Maker Ready To Produce 10 Million Doses

Handout file photo dated March 2, 2021 of and operator in Bavarian Nordic vaccine manufacturing line in Kvistgard, Denmark. Danish drugmaker Bavarian Nordic said Thursday it was ready to produce up to 10 million doses of its vaccine targeting mpox by 2025 after the World Health Organization declared a surge in the virus in Africa a global public health emergency. Alarmed by a rise in cases in the Democratic Republic of Congo and the spread of mpox to nearby countries, WHO experts said Wednesday that the "situation constitutes a public health emergency of international concern". Photo by Bavarian Nordic via ABACAPRESS.COM

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi (2nd L) speaks at a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi speaks at a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- The headquarters of Kobayashi Pharmaceutical is seen in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi attends a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi (2nd L) and others bow at a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

2 die, 100 hospitalized after consuming Japan drugmaker's supplements

OSAKA,Japan, March 27 Kyodo - Two people are believed to have died and over 100 hospitalized after consuming red yeast rice dietary supplements from Kobayashi Pharmaceutical Co., the Japanese drugmaker and the health ministry said Tuesday, amid swelling safety concerns over the products.(Kyodo)

E

Japanese drugmaker sees opportunities at China import expo

STORY: Japanese drugmaker sees opportunities at China import expo SHOOTING TIME: Nov. 9, 2023 DATELINE: Nov. 10, 2023 LENGTH: 00:00:49 LOCATION: SHANGHAI, China CATEGORY: ECONOMY SHOTLIST: 1. various of Takeda's exhibits at the sixth CIIE 2. SOUNDBITE (Chinese): SHAN GUOHONG, Senior vice president of Takeda and president of Takeda China STORYLINE: Takeda Pharmaceutical, one of Japan's biggest drugmakers, is a "frequenter" at this year's China International Import Expo (CIIE) in Shanghai. Over the past six years, China has grown to be Takeda's third largest market globally. And the company's Chinese subsidiary has developed into one of the best-performing transnational pharmaceutical firms in China. SOUNDBITE (Chinese): SHAN GUOHONG, Senior vice president of Takeda and president of Takeda China "We are very pleased to be able to participate in the CIIE every year. This platform enables us to swiftly bring our global innovation achievements to China. In the future, we will continue to strengthen our coop

E

Major Chinese pharmaceutical company expands into Japan

NAGOYA, Japan - Hengrui Medicine Japan President Makoto Shimada attends a press conference in Nagoya, Japan, on July 22, 2014. Major Chinese drugmaker Jiangsu Hengrui Medicine Co. said that day it has established a Japanese subsidiary in Nagoya to sell anticancer drugs in Japan.

E

Novartis Pharma

TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.

E

Otsuka ties up with Denmark's Lundbeck on psychiatric drugs

TOKYO, Japan - Otsuka Pharmaceutical Co. President Taro Iwamoto and Danish drugmaker H. Lundbeck A/S CEO Ulf Wiinberg shake hands in Tokyo on Nov. 11, 2011. The two companies agreed to share costs to develop and market drugs to treat central neurological diseases including schizophrenia.

E

Takeda to acquire Swiss drugmaker

TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa makes an announcement at a press conference in Tokyo on May 19, 2011. The largest Japanese drugmaker has signed an agreement with the shareholders of Swiss drugmaker Nycomed S/A to acquire all shares in the Swiss firm for 9.6 billion euros (about 1 trillion yen).

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Supporters of plaintiffs hold up banners in front of the Osaka District Court on Feb. 25, 2011, declaring victory in their case after the court ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine of 11 plaintiffs who sought compensation over side-effects caused by the lung cancer drug Iressa.

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Hideki Shimizu (R), a plaintiff who demanded compensation over side effects caused by the lung cancer drug Iressa, speaks at a press conference in Osaka on Feb. 25, 2011, together with Akio Chikazawa, a plaintiff in a similar suit filed in Tokyo. The Osaka District Court the same day ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine out of 11 plaintiffs, including Shimizu.

E

Mitsubishi Tanabe recalls drugs

TOKYO, Japan - Mitsubishi Tanabe Pharma Corp. President Michihiro Tsuchiya (2nd from L) bows in apology during a press conference in Tokyo on Jan. 26, 2011. The drugmaker initiated a voluntary recall of three injection solution products that one of its subsidiaries may have shipped without conducting quality tests.

E

Mitsubishi Tanabe recalls drugs

TOKYO, Japan - Mitsubishi Tanabe Pharma Corp. President Michihiro Tsuchiya (front) bows in apology during a press conference in Tokyo on Jan. 26, 2011. The drugmaker initiated a voluntary recall of three injection solution products that one of its subsidiaries may have shipped without conducting quality tests.

E

Otsuka Holdings debuts on Tokyo bourse

TOKYO, Japan - Tatsuo Higuchi, president of drugmaker Otsuka Holdings Co., speaks at a news conference in Tokyo on Dec. 15, 2010 after the company made its debut on the Tokyo Stock Exchange's First Section.

E

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker.

E

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

OSAKA, Japan - Photo taken Sept. 3 shows the headquarters of Dainippon Sumitomo Pharma Co. in Osaka. The company said the same day it has agreed to buy out Sepracor Inc., a Massachusetts-based pharmaceutical maker, for around $2.6 billion in an attempt to tap into the U.S. market.

E

Drugmaker Kowa, Israel's Teva plan joint generic drug firm

TOKYO, Japan - Shlomo Yanai (L), president and chief executive officer of Israel's Teva Pharmaceutical Industries Ltd., and Yoshihiro Miwa, president of Japanese drugmaker Kowa Co., shake hands during a press conference in Tokyo on Sept. 24 at which they announced the two companies will set up a joint generic drug company in Tokyo next year.

E

Kirin to acquire drugmaker Kyowa Hakko

TOKYO, Japan - (From L to R) Kirin Pharma Co. President Katsuhiko Asano, Kirin Holdings Co. President Kazuyasu Kato and Kyowa Hakko Kogyo Co. President Yuzuru Matsuda join hands in Tokyo on Oct. 22. Kirin Holdings said the same day it will acquire major pharmaceutical firm Kyowa Hakko and launch a tender offer of 1,500 yen per Kyowa Hakko share on Oct. 31.

E

Taisho, Tanabe drugmakers to merge next April

TOKYO, Japan - Akira Uehara (R), president of Japan's Taisho Pharmaceutical Co., and Toshio Tanaka, president of Tanabe Seiyaku Co., another Japanese drugmaker, shake hands during a news conference at a Tokyo hotel on Sept. 17. They announced an integration of their business operations next year in a bid to survive the intensifying race in the domestic pharmaceuticals market, the world's second largest.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi (C), president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi, president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi

The headquarters building of Japanese drugmaker Shionogi & Co. is pictured in Osaka on Dec. 27, 2021.

E

Japan halts use of 1.63 mil. Moderna vaccine doses over contamination

Japan's health ministry said Thursday foreign materials were found in some portions of unused doses of Moderna Inc.'s COVID-19 vaccine and the use of around 1.63 million doses manufactured in the same production line has been suspended as a precaution. Japanese drugmaker Takeda Pharmaceutical Co., which is in charge of sales and distribution of the vaccine in the country, said it has yet to see any reports of safety issues. Some of the 1.63 million doses distributed to 863 vaccination centers have already been used. The size of foreign substances confirmed in 39 vials is believed to be a few millimeters, with their elements being unknown. Moderna is conducting an investigation into the materials, according to the ministry and Takeda. The Ministry of Health, Labor and Welfare said foreign substances have been confirmed since Aug. 16 at eight vaccination sites in the prefectures of Ibaraki, Saitama, Tokyo, Gifu and Aichi. Takeda reported them to the ministry on Wednesday.

E

Kirin to acquire drugmaker Kyowa Hakko

TOKYO, Japan - (From L to R) Kirin Pharma Co. President Katsuhiko Asano, Kirin Holdings Co. President Kazuyasu Kato and Kyowa Hakko Kogyo Co. President Yuzuru Matsuda join hands in Tokyo on Oct. 22. Kirin Holdings said the same day it will acquire major pharmaceutical firm Kyowa Hakko and launch a tender offer of 1,500 yen per Kyowa Hakko share on Oct. 31. (Kyodo)

E

Drugmaker Kowa, Israel's Teva plan joint generic drug firm

TOKYO, Japan - Shlomo Yanai (L), president and chief executive officer of Israel's Teva Pharmaceutical Industries Ltd., and Yoshihiro Miwa, president of Japanese drugmaker Kowa Co., shake hands during a press conference in Tokyo on Sept. 24 at which they announced the two companies will set up a joint generic drug company in Tokyo next year. (Kyodo)

E

COVID-19 vaccine developed by Pfizer

Photo taken Feb. 17, 2021, shows vials of COVID-19 vaccine developed by U.S. drugmaker Pfizer Inc., at a hospital in Ichihara, Chiba Prefecture. Japan began administering COVID-19 vaccinations the same day, with health workers being first to get them.

E

COVID-19 vaccine developed by Pfizer

Photo taken Feb. 17, 2021, shows a vial of COVID-19 vaccine developed by U.S. drugmaker Pfizer Inc., at a hospital in Ichihara, Chiba Prefecture. Japan began administering COVID-19 vaccinations the same day, with health workers being first to get them.

E

COVID-19 vaccine developed by Pfizer

Photo taken Feb. 17, 2021, shows vials of COVID-19 vaccine developed by U.S. drugmaker Pfizer Inc., at a hospital in Ichihara, Chiba Prefecture. Japan began administering COVID-19 vaccinations the same day, with health workers being first to get them.

E

Japan launches COVID-19 vaccinations

Photo shows a COVID-19 vaccine developed by U.S. drugmaker Pfizer Inc. at Chiba Rosai Hospital in Chiba Prefecture on Feb. 17, 2021. Japan began administering COVID-19 vaccinations the same day, with health workers first to get them.

E

Takeda Pharmaceutical President Weber

Takeda Pharmaceutical Co. President Christophe Weber speaks in an interview with Kyodo News in Tokyo on May 9, 2018, following the company's deal to acquire Irish drugmaker Shire Plc. (Kyodo) ==Kyodo

E

Takeda to acquire Swiss drugmaker

TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa makes an announcement at a press conference in Tokyo on May 19, 2011. The largest Japanese drugmaker has signed an agreement with the shareholders of Swiss drugmaker Nycomed S/A to acquire all shares in the Swiss firm for 9.6 billion euros (about 1 trillion yen). (Kyodo)

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Hideki Shimizu (R), a plaintiff who demanded compensation over side effects caused by the lung cancer drug Iressa, speaks at a press conference in Osaka on Feb. 25, 2011, together with Akio Chikazawa, a plaintiff in a similar suit filed in Tokyo. The Osaka District Court the same day ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine out of 11 plaintiffs, including Shimizu. (Kyodo)

E

AstraZeneca ordered to pay damages over side-effects of Iressa

OSAKA, Japan - Supporters of plaintiffs hold up banners in front of the Osaka District Court on Feb. 25, 2011, declaring victory in their case after the court ordered the Japan unit of British drugmaker AstraZeneca PLC to pay a total of 60.5 million yen to nine of 11 plaintiffs who sought compensation over side-effects caused by the lung cancer drug Iressa. (Kyodo)

E

Mitsubishi Tanabe recalls drugs

TOKYO, Japan - Mitsubishi Tanabe Pharma Corp. President Michihiro Tsuchiya (front) bows in apology during a press conference in Tokyo on Jan. 26, 2011. The drugmaker initiated a voluntary recall of three injection solution products that one of its subsidiaries may have shipped without conducting quality tests. (Kyodo)

E

Mitsubishi Tanabe recalls drugs

TOKYO, Japan - Mitsubishi Tanabe Pharma Corp. President Michihiro Tsuchiya (2nd from L) bows in apology during a press conference in Tokyo on Jan. 26, 2011. The drugmaker initiated a voluntary recall of three injection solution products that one of its subsidiaries may have shipped without conducting quality tests. (Kyodo)

E

Otsuka Holdings debuts on Tokyo bourse

TOKYO, Japan - Tatsuo Higuchi, president of drugmaker Otsuka Holdings Co., speaks at a news conference in Tokyo on Dec. 15, 2010 after the company made its debut on the Tokyo Stock Exchange's First Section. (Kyodo)

E

Otsuka ties up with Denmark's Lundbeck on psychiatric drugs

TOKYO, Japan - Otsuka Pharmaceutical Co. President Taro Iwamoto and Danish drugmaker H. Lundbeck A/S CEO Ulf Wiinberg shake hands in Tokyo on Nov. 11, 2011. The two companies agreed to share costs to develop and market drugs to treat central neurological diseases including schizophrenia. (Kyodo)

E

Drugmaker Shionogi testing coronavirus vaccine candidate

Isao Teshirogi, president of Japanese pharmaceutical maker Shionogi & Co., gives an interview in Osaka on Dec. 16, 2020. Shionogi has conducted clinical testing for its coronavirus vaccine candidate.

E

Drugmaker Shionogi testing coronavirus vaccine candidate

Isao Teshirogi, president of Japanese pharmaceutical maker Shionogi & Co., gives an interview in Osaka on Dec. 16, 2020. Shionogi has conducted clinical testing for its coronavirus vaccine candidate.

E

Drugmaker Shionogi testing coronavirus vaccine candidate

Isao Teshirogi, president of Japanese pharmaceutical maker Shionogi & Co., gives an interview in Osaka on Dec. 16, 2020. Shionogi has conducted clinical testing for its coronavirus vaccine candidate.

E

Tokyo stock surge

A roadside financial data screen in Tokyo shows the 225-issue Nikkei Stock Average rising above the 26,000 mark for the first time in over 29 years on the morning of Nov. 17, 2020, as progress by a U.S. drugmaker in developing a coronavirus vaccine improved sentiment.

E

Tokyo stock surge

A roadside financial data screen in Tokyo shows the 225-issue Nikkei Stock Average rising above the 26,000 mark for the first time in over 29 years on the morning of Nov. 17, 2020, as progress by a U.S. drugmaker in developing a coronavirus vaccine improved sentiment.

E

Fujifilm to buy Biogen unit

Fujifilm Holdings Corp. President Shigetaka Komori meets the press in Tokyo on March 12, 2019, over the company's plan to buy a unit of U.S. drugmaker Biogen Inc. (Kyodo) ==Kyodo